IGF2BP2 and metabolic dysfunction-associated steatohepatitis: Of pathophysiological significance, hepatic IGF2BP2 expression is upregulated in NASH mice and patients, suggesting that suppression of IGF2BP2 may serve as a promising therapeutic target for treating this disease.